Skip to main content
Clinical Trials/NCT05122793
NCT05122793
Active, not recruiting
Not Applicable

"HerzCheck" - Erkennung Und Prävention Einer Frühen Herzinsuffizienz Mittels Telemedizinischer Verfahren in Strukturschwachen Regionen

German Heart Institute1 site in 1 country4,509 target enrollmentJune 21, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
German Heart Institute
Enrollment
4509
Locations
1
Primary Endpoint
Improved GLS
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

This study is intended to provide a basis for decision-making for the improved medical care of patients with asymptomatic heart failure, especially in structurally weak regions.

Detailed Description

The aim of the study is the early detection of asymptomatic heart failure with a quality-assured cardiac screening MRI in the population in structurally weak regions and especially in patients with risk factors for the occurrence of heart failure. The diagnosis is followed by early initiation of appropriate therapeutic measures to improve the prognosis of the affected patients, avoid hospitalisations and save therapy costs, and is combined with recommended measures to minimise risk factors for the development of heart failure. The project includes a prospective, monocentric, randomised controlled clinical trial with blinded assessment of the endpoint (PROBE design). Within the scope of the study, 4,509 patients aged between 40 and 69 years who have characteristic risk factors for the development of heart failure were examined using a mobile cardiac screening MRI in the federal states of Brandenburg and Mecklenburg-Western Pomerania within Germany.

Registry
clinicaltrials.gov
Start Date
June 21, 2021
End Date
September 30, 2034
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
German Heart Institute
Responsible Party
Principal Investigator
Principal Investigator

Sebastian Kelle

Dr. Sebastian Kelle (MD)

German Heart Institute

Eligibility Criteria

Inclusion Criteria

  • Hypercholesterolaemia
  • Arterial hypertension
  • Chronic diabetes mellitus
  • Chronic kidney disease
  • Health insurance

Exclusion Criteria

  • Previously diagnosed Heart Failure
  • MRI-exclusion criteria

Outcomes

Primary Outcomes

Improved GLS

Time Frame: 12 months

Improved GLS at after one year compared to baseline.

Secondary Outcomes

  • Body weight in kilograms and body height in meters will be aggregated to report BMI in kg/m^2(12 months)
  • Systolic and diastolic blood pressure in mmHg(12 months)
  • Heart rate in BPM(12 months)
  • Quality of life questionnaire 1 in Likert scale(12 months)
  • Quality of life questionnaire 2 in Likert scale(12 months)
  • laboratory parameters: Iron, transferrin and creatinine(12 months)
  • laboratory parameters: Sodium, potassium, chloride, total cholesterol, triglycerides, HDL cholesterole, LDL cholesterole, hemoglobin and MCHC(12 months)
  • laboratory parameters: White cells and platelets(12 months)
  • laboratory parameters: MCV(12 months)
  • laboratory parameters: RDW-SD(12 months)
  • laboratory parameter: HbA1c(12 months)
  • laboratory parameter: red cells(12 months)
  • laboratory parameter: MCH(12 months)
  • laboratory parameter: hematocrit(12 months)
  • laboratory parameter: NT-proBNP(12 months)
  • laboratory parameter: transferrin saturation(12 months)
  • laboratory parameter: ferritin(12 months)
  • hospitalisations of cardiac origin, arrhythmias or death(12 months)
  • Laboratory parameters: urine albumin-creatinine ratio(12 months)

Study Sites (1)

Loading locations...

Similar Trials